The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
KL-50-based compounds are a promising new strategy for the treatment of MGMT-deficient, MMR-deficient GBM that recurs after frontline TMZ.
Authors
- Matthew McCord (ORCID: https://orcid.org/0000-0001-7673-4463)
- Craig Horbinski (ORCID: https://orcid.org/0000-0001-8340-9992)
- Jann Nagina Sarkaria (ORCID: https://orcid.org/0000-0001-7489-4885)
- Shejuan An
- Bruce Ruggeri (ORCID: https://orcid.org/0009-0002-0095-873X)
- Ranjit S. Bindra (ORCID: https://orcid.org/0000-0002-3255-0467)
- Thomas Sears (ORCID: https://orcid.org/0000-0003-3834-2439)
- Susan Gueble
- Rahul Kishore Chaliparambil (ORCID: https://orcid.org/0000-0002-4345-5393)
- Wenxia Wang (ORCID: https://orcid.org/0000-0001-9861-418X)
- C. David James
Institutions
- Northwestern University (US)
- Mayo Clinic (US)
- Yale University (US)
- Mayo Clinic in Arizona (US)
- Melinta Therapeutics (United States) (US)
- Mayo Clinic in Florida (US)
- Neurological Surgery (US)
- University of Virginia (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1093/neuonc/noae257
- Citations
- 7
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.07
Funders
- Northwestern University
- National Institutes of Health